Health Economics›Non-small cell lung cancer›Neoadjuvant therapy

Neoadjuvant therapy

Non-small cell lung cancer · 13 regimens

Cost estimates only — modelled on a typical patient (BSA 1.7 m², 70 kg, CrCl 90 mL/min) using the cheapest available formulary presentation. Excludes vial wastage, facility fees, supportive care, and infusion consumables. Not for billing, formulary decisions, or clinical use.

FiltersBiomarker

Y-axis

Cost vs Efficacy · 3 points

Fully pricedPartial pricing

Regimen	Biomarker	Cost/cycle ↓	Cycle	PFS ↕	OS ↕	Est. cycles	Course cost ↕	Evidence
Cisplatin and Docetaxel (DC) and Durvalumab Variant #01	—	R 68 696	21d	—	—	—	—	—
Cisplatin and Gemcitabine (GC) Variant #34	—	R 15 338	56d	48.0 mo	93.6 mo	27	R 414 127 PFS proxy	—
MIC Variant #02	—	R 7 668	21d	—	31.5 mo	—	—	1
Carboplatin and Paclitaxel (CP) Variant #38	—	R 5 031	21d	—	—	—	—	2
Cisplatin and Etoposide (EP) Variant #01	—	R 4 264	42d	—	~7.6 mo	—	—	1
Cisplatin and Vinorelbine (CVb) Variant #11	—	R 4 117	42d	—	—	—	—	1
Carboplatin and Paclitaxel (CP) and Nivolumab Variant #01 Partial	—	R 2 239	21d	—	—	—	—	2
Cisplatin and Docetaxel (DC) and Nivolumab Variant #01 Partial	—	R 2 031	21d	—	—	—	—	1
Cisplatin and Pemetrexed Variant #01	EGFR	R 1 088	21d	~5.6 mo	~14.1 mo	~9	~R 9 788 PFS proxy · indirect	25
Cisplatin and Vinorelbine (CVb) and Nivolumab Variant #01 Partial	—	R 861	21d	—	—	—	—	1
Cisplatin and Docetaxel (DC) N/A - secondary systemic drug	—	R 449	21d	—	—	—	—	1
Carboplatin and Pemetrexed N/A - secondary systemic drug	EGFR	R 52	21d	~5.6 mo	~13.8 mo	~9	~R 469 PFS proxy · indirect	25
No neoadjuvant therapy Partial	—	—	—	26.4 mo	48.0 mo	—	—	2

13 of 13 regimens shown